vs

Side-by-side financial comparison of ARGAN INC (AGX) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.

ARGAN INC is the larger business by last-quarter revenue ($251.2M vs $196.9M, roughly 1.3× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -2.3%). ARGAN INC produced more free cash flow last quarter ($171.9M vs $43.5M). Over the past eight quarters, ARGAN INC's revenue compounded faster (23.5% CAGR vs 8.5%).

Argan Inc. is a diversified holding company that provides comprehensive engineering, construction, project management and consulting services. Its core operating segments focus on power generation, telecommunications, industrial infrastructure and renewable energy projects, primarily serving public and private sector clients across North America.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

AGX vs PCRX — Head-to-Head

Bigger by revenue
AGX
AGX
1.3× larger
AGX
$251.2M
$196.9M
PCRX
Growing faster (revenue YoY)
PCRX
PCRX
+7.4% gap
PCRX
5.1%
-2.3%
AGX
More free cash flow
AGX
AGX
$128.4M more FCF
AGX
$171.9M
$43.5M
PCRX
Faster 2-yr revenue CAGR
AGX
AGX
Annualised
AGX
23.5%
8.5%
PCRX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AGX
AGX
PCRX
PCRX
Revenue
$251.2M
$196.9M
Net Profit
$30.7M
Gross Margin
18.7%
79.5%
Operating Margin
13.0%
1.2%
Net Margin
12.2%
Revenue YoY
-2.3%
5.1%
Net Profit YoY
9.7%
EPS (diluted)
$2.17
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGX
AGX
PCRX
PCRX
Q4 25
$251.2M
$196.9M
Q3 25
$237.7M
$179.5M
Q2 25
$193.7M
$181.1M
Q1 25
$232.5M
$168.9M
Q4 24
$257.0M
$187.3M
Q3 24
$227.0M
$168.6M
Q2 24
$157.7M
$178.0M
Q1 24
$164.6M
$167.1M
Net Profit
AGX
AGX
PCRX
PCRX
Q4 25
$30.7M
Q3 25
$35.3M
$5.4M
Q2 25
$22.6M
$-4.8M
Q1 25
$31.4M
$4.8M
Q4 24
$28.0M
Q3 24
$18.2M
$-143.5M
Q2 24
$7.9M
$18.9M
Q1 24
$12.0M
$9.0M
Gross Margin
AGX
AGX
PCRX
PCRX
Q4 25
18.7%
79.5%
Q3 25
18.6%
80.9%
Q2 25
19.0%
77.4%
Q1 25
20.5%
79.7%
Q4 24
17.2%
78.7%
Q3 24
13.7%
76.9%
Q2 24
11.4%
75.1%
Q1 24
14.4%
71.6%
Operating Margin
AGX
AGX
PCRX
PCRX
Q4 25
13.0%
1.2%
Q3 25
12.6%
3.5%
Q2 25
12.6%
4.7%
Q1 25
14.1%
1.2%
Q4 24
11.8%
13.2%
Q3 24
8.2%
-82.8%
Q2 24
4.1%
15.9%
Q1 24
7.1%
7.9%
Net Margin
AGX
AGX
PCRX
PCRX
Q4 25
12.2%
Q3 25
14.8%
3.0%
Q2 25
11.6%
-2.7%
Q1 25
13.5%
2.8%
Q4 24
10.9%
Q3 24
8.0%
-85.1%
Q2 24
5.0%
10.6%
Q1 24
7.3%
5.4%
EPS (diluted)
AGX
AGX
PCRX
PCRX
Q4 25
$2.17
$0.05
Q3 25
$2.50
$0.12
Q2 25
$1.60
$-0.11
Q1 25
$2.26
$0.10
Q4 24
$2.00
$0.38
Q3 24
$1.31
$-3.11
Q2 24
$0.58
$0.39
Q1 24
$0.89
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGX
AGX
PCRX
PCRX
Cash + ST InvestmentsLiquidity on hand
$423.7M
$238.4M
Total DebtLower is stronger
$372.2M
Stockholders' EquityBook value
$419.7M
$693.1M
Total Assets
$1.1B
$1.3B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGX
AGX
PCRX
PCRX
Q4 25
$423.7M
$238.4M
Q3 25
$275.5M
$246.3M
Q2 25
$304.3M
$445.9M
Q1 25
$298.4M
$493.6M
Q4 24
$299.8M
$484.6M
Q3 24
$302.0M
$453.8M
Q2 24
$291.8M
$404.2M
Q1 24
$306.5M
$325.9M
Total Debt
AGX
AGX
PCRX
PCRX
Q4 25
$372.2M
Q3 25
$376.7M
Q2 25
$580.5M
Q1 25
$583.4M
Q4 24
$585.3M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AGX
AGX
PCRX
PCRX
Q4 25
$419.7M
$693.1M
Q3 25
$393.2M
$727.2M
Q2 25
$363.9M
$757.8M
Q1 25
$351.9M
$798.5M
Q4 24
$328.7M
$778.3M
Q3 24
$308.1M
$749.6M
Q2 24
$293.2M
$879.3M
Q1 24
$290.9M
$892.2M
Total Assets
AGX
AGX
PCRX
PCRX
Q4 25
$1.1B
$1.3B
Q3 25
$882.7M
$1.3B
Q2 25
$792.2M
$1.5B
Q1 25
$836.2M
$1.6B
Q4 24
$768.9M
$1.6B
Q3 24
$726.6M
$1.5B
Q2 24
$624.4M
$1.6B
Q1 24
$598.2M
$1.6B
Debt / Equity
AGX
AGX
PCRX
PCRX
Q4 25
0.54×
Q3 25
0.52×
Q2 25
0.77×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGX
AGX
PCRX
PCRX
Operating Cash FlowLast quarter
$172.5M
$43.7M
Free Cash FlowOCF − Capex
$171.9M
$43.5M
FCF MarginFCF / Revenue
68.4%
22.1%
Capex IntensityCapex / Revenue
0.2%
0.1%
Cash ConversionOCF / Net Profit
5.61×
TTM Free Cash FlowTrailing 4 quarters
$283.0M
$136.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGX
AGX
PCRX
PCRX
Q4 25
$172.5M
$43.7M
Q3 25
$34.6M
$60.8M
Q2 25
$35.3M
$12.0M
Q1 25
$44.6M
$35.5M
Q4 24
$31.8M
$33.1M
Q3 24
$73.5M
$53.9M
Q2 24
$17.7M
$53.2M
Q1 24
$24.6M
$49.1M
Free Cash Flow
AGX
AGX
PCRX
PCRX
Q4 25
$171.9M
$43.5M
Q3 25
$32.9M
$57.0M
Q2 25
$34.9M
$9.3M
Q1 25
$43.3M
$26.9M
Q4 24
$29.2M
$31.0M
Q3 24
$71.1M
$49.8M
Q2 24
$17.4M
$51.6M
Q1 24
$24.0M
$46.3M
FCF Margin
AGX
AGX
PCRX
PCRX
Q4 25
68.4%
22.1%
Q3 25
13.8%
31.7%
Q2 25
18.0%
5.1%
Q1 25
18.6%
15.9%
Q4 24
11.4%
16.6%
Q3 24
31.3%
29.6%
Q2 24
11.0%
29.0%
Q1 24
14.6%
27.7%
Capex Intensity
AGX
AGX
PCRX
PCRX
Q4 25
0.2%
0.1%
Q3 25
0.7%
2.2%
Q2 25
0.2%
1.5%
Q1 25
0.6%
5.1%
Q4 24
1.0%
1.1%
Q3 24
1.0%
2.4%
Q2 24
0.2%
0.9%
Q1 24
0.4%
1.7%
Cash Conversion
AGX
AGX
PCRX
PCRX
Q4 25
5.61×
Q3 25
0.98×
11.20×
Q2 25
1.57×
Q1 25
1.42×
7.37×
Q4 24
1.13×
Q3 24
4.04×
Q2 24
2.24×
2.82×
Q1 24
2.05×
5.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGX
AGX

Power Industry Services$195.5M78%
Industrial Construction Services$49.4M20%
Telecommunications Infrastructure Services$6.3M3%

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

Related Comparisons